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Objective: The aim of this study was to identify a readily available, reproduc-
ible, and internationally applicable cost assessment tool for surgical procedures.
Summary of Background Data: Strong economic pressure exists worldwide
to slow down the rising of health care costs. Postoperative morbidity
significantly impacts on cost in surgical patients. The comprehensive com-
plication index (CCI1), reflecting overall postoperative morbidity, may
therefore serve as a new marker for cost.
Methods: Postoperative complications and total costs from a single tertiary
center were prospectively collected (2014 to 2016) up to 3 months after
surgery for a variety of abdominal procedures (n ¼ 1388). CCI1 was used to
quantify overall postoperative morbidity. Pearson correlation coefficient
(rpears) was calculated for cost and CCI
1. For cost prediction, a linear
regression model based on CCI1, age, and type of surgery was developed
and validated in an international cohort of patients.
Results: We found a high correlation between CCI1 and overall cost (rpears ¼
0.75) with the strongest correlation for more complex procedures. The prediction
model performed very well (R2 ¼ 0.82); each 10-point increase in CCI1
corresponded to a 14% increase to the baseline cost. Additional 12% of
baseline cost must be added for patients older than 50 years, or 24% for those
over 70 years. The validation cohorts showed a good match of predicted and
observed cost.
Conclusion: Overall postoperative morbidity correlates highly with cost. The
CCI1 together with the type of surgery and patient age is a novel and reliable
predictor of expenses in surgical patients. This finding may enable objective
cost comparisons among centers, procedures, or over time obviating the need
to look at complex country-specific cost calculations (www.assessurgery.com).
Keywords: CCI1, complications, cost, morbidity, surgery
(Ann Surg 2018;268:784–791)
H ealth care costs are consistently rising worldwide, implicatingeconomic threats in many countries.1 Great variations in health
care cost exist among countries ranging from 5.1% gross domestic
product (GDP) in Romania to 18.3% GDP in the United States.2,3
Currently, no reliable and internationally applicable method is
available for cost assessment in surgical patients.
Postoperative complications are known to be the most influ-
ential catalyzer of costs.4–6 While the assessment of complications is
still widely inconsistent, cost evaluation and comparison appear even
more difficult. The comprehensive complication index (CCI1)7,8
captures overall postoperative morbidity by severity, based on a prior
ranking by the Clavien Dindo system.9 This system, based on the
resources needed to treat any single complication, is currently the
most widely used grading of individual complications in many
surgical fields.7,10 The CCI1 is a validated metric for postoperative
morbidity ranging from 0 (no complication) to 100 (death), which
was developed on the basis of patient and physician perspectives.7,11
We hypothesize that assessing CCI1may concomitantly best inform
about the total cost of a procedure, as it allows to trace cumulative
progression of postoperative morbidity over time. This approach
builds on the previous observation that already the most severe
postoperative complication alone was found to correlate well with
the procedure cost.4
Our aim was, therefore, to test the value of CCI1 as a marker
of cost after general and complex abdominal surgical procedures in a
single tertiary center, and validate the predictive model in subsequent
cohort of patients from the study center, as well as in an international,
multicentric cohort of surgical patients.
METHODS
Study Design and Population
From a prospectively maintained database, we created 3
cohorts of patients undergoing general and complex abdominal
surgery and followed them for up to 3 months after surgery. The
first cohort consisted of patients from the Department of Surgery and
Transplantation at the University Hospital Zurich, Switzerland, who
received in 2014 or 2015 cholecystectomy; colon or rectum resec-
tions; liver, pancreas, bariatric surgeries, or liver transplantation
(LT). This cohort served to develop the tool for cost prediction.
The second cohort, used for a first, temporal validation of the cost
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prediction tool, consisted of patients undergoing these procedures in
2016. The third cohort, used for the second, external validation,
consisted of patients from 6 international tertiary centers across
Europe and the USA, who received surgery between 2014 and
2016. The selection of internal centers was based on available
prospective data at the respective centers. Data on pancreas surgery
were provided from the University Hospital of Lyon, France, and the
Johns Hopkins School of Medicine, Baltimore, MD. For liver
surgery, cases were added from the Humanitas Hospital, Milan,
Italy, the Hepato-Biliary-Pancreatic and Transplantation Centre,
Curry Cabral Hospital, Lisbon, Portugal, and the Hospital Clinic
de Barcelona, Spain (2004 to 2014). Colon and rectum surgery data
were provided by the Bellvitge University Hospital, Barcelona,
Spain.
For each cohort, exclusion criteria were emergency surgeries,
robotic resections, and incidental resections. Surgery-specific inclu-
sion and exclusion criteria are provided in the Supplemental-Digital-
Content 1, http://links.lww.com/SLA/B442. In case of combined
surgeries, the more severe operation defined group allocation.
Measurements
All the studied patients of the Zurich cohorts were included in
prospective databases held by the respective sections of the Depart-
ment of Surgery. Complications and their treatment were gathered
from medical records, laboratory results, and doctor’s reports. The
CCI1 is the standard metric at the University Hospital Zurich for
overall postoperative morbidity.7,8 Each complication, graded by
Clavien Dindo classification,9 is recorded in the database and the
CCI1 was calculated accordingly by an online calculator (http://
www.cci.assessurgery.com).
The 3-month follow-up was chosen on the basis of recent
benchmark studies indicating that collection of data until discharge
only is inaccurate, and that most postoperative complications occur
within 3 months of surgery.12 For the international validation, the
same procedures were followed. However, cost data after discharge
were not available in each center due to the different ways postoper-
ative follow-up is organized. The validation of cost prediction was
conducted according to the available data.
Cost Assessment
For the University Hospital Zurich, the costs, and not the
charge, were calculated using the SAP system (SAP, Business
Warehouse, Walldorf, Germany),13 compliant to the standardized
cost accounting guidelines of the association of Swiss hospitals
(REKOLE).14 For full cost analysis, complete in-hospital and out-
patient expenses, including variable and fixed costs, were calculated
from hospital admission to up to the completion of the 3 months
observation period. The additional fees paid to doctors for private
insured patients were ignored. After discharged, cost caused by any
treatments or readmission was obtained again from the hospital
administration. For the international validation, each of the partici-
pating centers also obtained the total costs without additional fees or
charges from their respective hospital administration (Supplemental-
Digital-Content 2, http://links.lww.com/SLA/B442). Cost account-
ing was conducted according to the country-specific standards.
Statistical Analysis
The correlation assessment of overall postoperative morbidity
and total costs was calculated using the Pearson correlation coeffi-
cient (rpears) for both the Zurich and the international cohorts.
Referred reference values for strength of effect size were ‘‘very
weak’’ 0.00 to 0.19, ‘‘weak’’ 0.20 to 0.39, ‘‘moderate’’ 0.40 to 0.59,
‘‘strong’’ 0.60 to 0.79, and ‘‘very strong’’ 0.80 to 1.0.15 Due to the
skewedness of the data, the natural logarithm (ln) transformation of
costs was used. CCI1 data are presented as medians and interquartile
range (IQR).
To develop the cost prediction tool, a linear regression model
was fitted to the 2014 to 2015 data from Zurich (development cohort)
that included the CCI1, as well as 2 other easily accessible param-
eters: patient’s age and type of performed surgery. The choice of the 2
additional parameters is based on the previous findings that costs of
similar complications vary between different types of surgery.4
Parameters for comorbidity assessment, such as the commonly used
ASA classification16 or Charlson Comorbidity Index,17 were delib-
erately reframed from, as there are no precise measures of comor-
bidity or their severity. In addition, both have been determined to be
inferior to complications regarding cost prediction.4 Further, comor-
bidities are approximated well by the age of the patients and the type
of surgery performed. With increasing age, the number and severity
of comorbidities increase. Type of surgery also gives some indication
of possible comorbidities (eg, bariatric surgery: common comorbid-
ities are diabetes and high blood pressure). With the aim to keep this
cost assessment method simple, we chose the easy assessable
information age and surgery type, as no further grading is necessary.
To validate the cost prediction tool, we first predicted the cost,
based on the model developed in the Zurich 2014 to 2015 cohort, for
the Zurich patients from 2016 (temporal validation). Correlation of
predicted and observed costs was calculated by Pearson correlation
coefficient. Agreement of the 2 methods (prediction and observation)
was assessed by Bland-Altman plot and conditional quantile. We
then repeated this validation in the international cohort with patients
from 5 European and 1 northern American country. For all statistical
analyses, the program R was used.18
RESULTS
Characteristics of the Zurich and International
Cohorts
In the 2 Zurich cohorts, a total of 1388 patients were included
in the analysis: 357 of those received cholecystectomies; 134 colon,
107 rectum, 168 liver, 74 pancreas, and 408 bariatric surgeries.
Finally, 140 patients received LT (Table 1).
International centers provided a total of 767 patients for the
validation part of the study, including 292 patients for pancreas
surgery (Lyon 48 patients and Baltimore 244 patients); 373 patients
for liver surgery (Milan 285, Lisbon 36, Barcelona 52); and 56
patients for colon resections and 46 patients for rectum resections
(Barcelona). Data were collected up to 3 months similar to the study
population, except for 4 centers (Lisbon, Lyon, Barcelona, Balti-
more), which could only accurately provide in-hospital cost data. For
these latter procedures, comparisons were done only with the CCI1
and related cost during the hospital stay.
Correlation Between Morbidity and Costs in the
Zurich Cohort
A strong correlation between CCI1 and costs was found up to
3 months postoperatively (rpears¼ 0.70) (Fig. 1). This correlation was
highest for the inpatient period (rpears¼ 0.75), while focusing only on
the postoperative course after discharge resulted in a weaker corre-
lation of CCI1 and cost (rpears ¼ 0.33).
Analysis According to Surgical Procedures
Further, we assessed CCI1/cost correlation of each type
of procedure. Of note, correlation in the surgical group increased
with higher morbidity, implying that the most complex procedures
disclosed the highest correlation of CCI1 and cost (Fig. 2, Table 1).
For example, this is demonstrated comparing pancreas surgery
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(rpears ¼ 0.85) to bariatric surgery (rpears ¼ 0.28). In contrast to the
complexity of the surgery, LT displayed a relatively weak correlation
(rpears ¼ 0.66). The surgical groups with weak correlation did not
significantly influence the overall correlation strength.
Development of the Cost Prediction Tool
The linear regression model predicted cost very well (R2 ¼
0.82) (Supplemental-Digital-Content 3, http://links.lww.com/SLA/
B442). Each predictor was associated highly significantly with cost
in the multivariable model (individual value of each predictor:
surgery type R2 0.71, CCI1 R2 0.51, age R2 0.06). We found a
14% cost increase per 10 points of CCI1 increase during the first 3
months. Of note, the cost increase was 20% when considering only
the in-hospital period. Age had a significant influence on the weight
of complications on overall cost. For patients older than 50 years, an
extra 12% basic cost is added 1 time, independent of the CCI1. This
figure is 24% for patients older than 70 years.
Validations
Two different methods of validation were applied. The
first validation was performed in patients from the study
institution in Zurich, in which the prediction model, compiled
from the 2014 to 2015 period, was tested on the 2016 data. This
displayed a good match of the predicted and observed cost
(Figs. 3A, B, Supplemental Digital Content 4, http://links.
lww.com/SLA/B442). The comparison of predicted and
observed costs not only displayed a straight line but also matched
in absolute terms (Figs. 3A, B). The Bland-Altman plot shows that,
on average, there is no difference between predicted and observed
cost while displaying a moderate spread (Supplemental-Digital-
Content 4, http://links.lww.com/SLA/B442). The international
validation supported the findings. In the comparison of predicted
and observed costs, the results were located on a straight line,
however, parallel running to the perfect fit, showing a 27.8%
overestimation of costs (Figs. 3C, D). This was further
shown by the Bland-Altman plot, displaying a 1.3 deviation in
difference of the natural log of observed to predicted cost (Sup-
plemental Digital Content 4, http://links.lww.com/SLA/B442).
The international validation data further confirmed the good
correlation of overall morbidity and cost (rpears ¼ 0.60)
with a minor decrease of strength for the hospitalization period
(rpears ¼ 0.53) (Table 1).
TABLE 1. Overview of Both Cohorts
(a) Zurich Cohort
Group (Total no.)
Median
Age, y
Median
Length of
Hospitalization,
d
No. of
Complications
up to 3 mo
(% Occurred
in Hospital)
Median
CCI1 3 mo
(IQR)
Median CCI1
Hospitalization
(IQR)
Median
Cost US $
(to Discharge)
rpears to 3 mo
Postop
rpears to
Discharge
All (1388) 53.4 10 2497 (56%) 8.7 (29.6) 0 (20.9) 22,059 (20,668) 0.70 0.74
Cholecystectomy (357) 53.3 4 212 (39%) 0 (8.7) 0 (0) 9,904 (9,324) 0.39 0.39
Colon resection (134) 65.4 11 236 (73%) 15.0 (24.2) 8.7 (20.9) 27,239 (23,538) 0.77 0.65
Rectum resections (107) 61.5 14 245 (52%) 17.3 (22.7) 4.4 (20.9) 34,105 (28,894) 0.70 0.83
Liver surgery (168) 60.2 12 342 (57%) 13.6 (31.1) 8.7 (22.6) 34,322 (31,459) 0.76 0.80
Pancreas surgery (74) 61.5 19 274 (59%) 30.5 (34.2) 20.9 (38.2) 60,159 (50,004) 0.85 0.90
Bariatric surgery (408) 43.0 6 465 (27%) 8.7 (26.2) 0 (0) 20,544 (19,656) 0.28 0.46
Liver transplant (140) 54.2 25 723 (73%) 49.6 (39.9) 40.2 (38.2) 136,369 (127,691) 0.66 0.64
(b) International Cohort
Group (Total no.),
Center
Median
Age, y
Median
Length of
Hospitalization,
d
No. of
Complications
up to 3 mo
(% Occurred
in Hospital)
Median
CCI1 3 mo
(IQR)
Median CCI1
Hospitalization
(IQR)
Median
Cost US $
(to Discharge)
rpears up to
3 mo
Postop
rpears up to
Discharge
All (523) 62.2 13 295 (88%) 0 (20.9) 0 (22.6) 11,387 (18,143) 0.60 0.53
Liver surgeries (285) 63.7 13 186 (91%) 0 (20.9) 0 (20.9) 11,098 (10,770) 0.55 0.55
Colon resections (56)y 69.0 10 32 (88%) 0 (20.9) 0 (20.9) 9,867 (8,319) 0.75 0.70
Rectum resections (46)y 66.5 14 41 (88%) 8.7 (29.6) 8.7 (20.9) 13,456 (11,397) 0.75 0.63
Pancreas surgery (244)z 64.7 11 – – 8.7 (22.6) – (50,074) – 0.66
Liver surgery (52)§ 35.4 11 – – 20.9 (22.1) – (20,587) – 0.53
Pancreas surgeries (48) 65.0 24 – – 0 (20.9) – (27,406) – 0.83
Liver surgeries (36)jj 60.1 10 – – 33.5 (24.5) – (54,384) – 0.60
a Zurich cohort: Median age, median length of hospitalization, number and severity of complications occurred overall and within the different surgical groups up to 3 months and
hospital discharge. Respective median costs in US dollars up to 3 months and hospital discharge. Correlation between cost and overall morbidity calculated by Pearson correlation
coefficient (rpears) using natural log transformation of costs.
b International cohort: Median age, median length of hospitalization, number and severity of complications occurred overall and within the different surgical groups up to 3 months
and hospital discharge. Respective median costs in US dollars up to 3 months and hospital discharge. Correlation between cost and overall morbidity calculated by Pearson correlation
coefficient (rpears) using natural log transformation of costs. For center 3–6, only in-hospital cost data available.Department of Surgery and Division of Hepatobiliary and General Surgery, Humanitas Research Hospital, Milan, Italy.
yDepartment of General and Digestive Surgery, Bellvitge University Hospital, University of Barcelona and IDIBELL, Barcelona, Spain.
zDepartment of Surgery, Johns Hopkins School of Medicine, Baltimore, MD.
§Department of Surgery, Hospital Clinic de Barcelona, Barcelona, Spain.
Department of General and Digestive Surgery, University Hospital of Lyon, Lyon, France
jjHepato-Biliary-Pancreatic and Transplantation Centre, Curry Cabral Hospital, CHLC, Lisbon, Portugal.
CCI
1
indicates Comprehensive Complication Index; IQR, interquartile range; rpears, Pearson correlation correlation coefficient.
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DISCUSSION
Assessing and restraining costs, while maintaining quality, is
currently one of the most relevant challenges in medicine. A simple
and validated marker of total cost of surgical procedures would be of
great value, particularly if applicable in different health care systems.
We present here the first evidence that overall postoperative morbid-
ity provides an excellent marker of cost for abdominal surgical
procedures. The validation studies in an international group of
patients suggest that the predictive model offers wide applicability
for cost assessment. From this inaugural study, linking postoperative
morbidity with overall cost of a procedures, we would like to
highlight 3 main observations.
First, the more complex the surgery, the stronger is the
correlation between overall morbidity and costs. Second, the more
meticulous and controlled the assessment of every complication, the
stronger the correlation, indicating the great importance to objec-
tively and fully register each complication. Third, cost in surgery are
predictable when using the easily accessible metric system CCI1,
patient age, and surgery type.
Surgical complications are the strongest driver of cost with the
highest savings potential.4 Importantly, severity, much more than the
type of complications, determines cost accumulation.4 Intending to
capture every postoperative complication, the CCI1 is therefore, a
more precise measure of morbidity than the recording of single
complications, typically with a focus limited to the most severe ones.
Furthermore, CCI1 encompasses the dimension of time into the
calculation, as additional complications during the further postoper-
ative course can easily be cumulated to the previous assessed values.
Thus, meticulous, standardized tracking of postsurgical complica-
tions is the basis to accurately predict costs. Every treatment
increases costs; thus, an incomplete complication assessment would
moderate the accuracy of predicting cost.
CCI1, like cost, increases by the severity and the number of
complications.7,8 Surgeries with a higher occurrence of serious
complications showed higher correlation between complications
and cost compared with simpler procedures. This finding is
demonstrated by the highest correlation for complex surgeries, such
as pancreas, liver, or rectum resections. In contrast, LT showed a
lower correlation of CCI1/cost despite being the most complex
procedure. This is likely due to the sensitivity of the correlation
coefficient to severe outliers, such as patients with high CCI1 but
surprisingly low cost (Supplemental-Digital-Content 5, http://links.
lww.com/SLA/B442).
On the basis of these results, we advocate the CCI1 as a
credible marker of cost due to the strong correlation of overall
morbidity and surgical case-costs. By adding surgery type and
patient’s age as surrogate parameters of surgical variations and
patients’ comorbidities, we developed and validated a cost prediction
model. The model indicates that, considering a 3-month follow-up,
for each raise of 10 points, CCI1 cost incrementally increased by
14% of the baseline value. Interestingly, patient age had an additional
influence on cost increase. Another 12% of the baseline cost must be
added once, independent of the level of CCI1, for patient older than
50 years of age, and 24% for those over 70 years. For example, a 60-
year-old-patient who underwent an abdominal procedure with a
baseline cost of $50,000. Her CCI1 at 3 months after surgery
was 50, which equals in total cost of $91,000 [$50,000 (baseline)þ
$35,000 (CCI1 50)þ $6000 (age > 50 years)]. Further examples
are presented in the Supplemental-Digital-Content 6, http://links.
lww.com/SLA/B442. In addition, we offer an online cost assessment
tool (www.assessurgery.com).
Hence, only knowing the basic cost of a procedure, an estimate
of total costs can be calculated. This novel method enables a cost
assessment independent of country-specific pricing-power, wages,
costs of drugs and medical devices, and outside of hospital admin-
istrations; burdensome, time delayed ascertainment of cost data can
be bypassed and inconsistencies in their calculations prevented. The
difficulty to collect all costs is shown in the parallel deviation of
predicted to observed costs in the international validation data
(Figs. 3C, D, Supplemental-Digital-Content 4, http://links.lww.
com/SLA/B442). The symmetry of this deviation illustrates not a
lack of accuracy of the prediction model, but most likely the
generally higher cost in Switzerland as well as the difficulties to
FIGURE 1. Correlation of CCI1 and log of total
costs of all 7 Zurich surgical groups combined
at 3 months postoperatively. Pearson correla-
tion coefficient (rpears).
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completely collect cost. After recalibration of the prediction model
for the international data by updating the intercept by -1.3, the results
ended up on the ideal line (Figs. 3E, F). This recalibrated model is
added to our online calculator for cost calculation outside
Switzerland.
Accepting CCI1 as an adequate marker of cost, we may see at
least 2 highly relevant implications, first in the diagnosis-related
group (DRG) reimbursement systems and second in benchmarking
surgical quality. In a medical system with DRG or similar cost
reimbursements, a standardized ‘‘price’’ is determined for each
procedure by the average cost of the intervention. However, the
calculation of patients’ individual CCI1would be a more logical and
transparent way for reimbursement of specific surgical cases. Some
may argue that such practice only promotes higher reimbursements
to hospitals with poorer surgical quality. Indeed, such reimbursement
system would only work, when the centers’ outcome is equally
assessed to a validated level of quality (eg, benchmark). In this
context, verified good surgical outcome would represent high surgi-
cal quality instead of the commonly equated center’s case load. Of
note, surgical outcome improvement analogue the economic-based
concept of benchmarking (improving products/processes by com-
parison with the best on the market) has caught increasing interest in
the surgical community in the past few years.12,19–21
There are a number of limitations in this inaugural study. First,
we only evaluated 7 abdominal procedure groups. How the CCI1
may inform on cost in other surgical fields, such as orthopedic,
cardiovascular, or neurosurgical procedures, needs to be further
investigated. Second, we did not extensively look at additional
predictors of cost, which may also have an impact. This was done
consciously to prevent creating a complicated, cumbersome formula,
which may likewise not gain acceptance in the surgical community.
Age is an objective surrogate marker of comorbidities and was highly
additive to the CCI1 in the prediction model. Third, while a 3-month
follow-up is adequate for most abdominal procedures, it is too short
for LT, which should cover 1 year, as documented in a recent
benchmark study.19 Fourth, our model may underestimate cost of
treatment in some extremely severe diseases, such as necrotizing
pancreatitis requiring multiple second looks/necrosectomies. It was
suggested to count planned successive laparotomies only once as
grade 3b complication. This should be reconsidered when using
FIGURE 2. Correlation of CCI1 and log of total costs of each of the 7 surgical groups fromZurich 3months postoperatively. Pearson
correlation coefficient (rpears).
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FIGURE 3. (A) Correlation of observed and predicted log costs of the Zurich validation data. (Natural log). (B) Conditional quantile
plot showing the correlation of observed and predicted log costs of the Zurich validation data, presented as median and the
interquartile ranges. The blue columns indicate the number of patients within the range (sections of 0.4) of predicted costs. (Natural
log). (C) Correlation of observed and predicted log costs of the international validation data. The shownmean deviation of log 1.3 of
observed to predicted costs corresponds to a 27.8%overestimation of costs. (Natural log). (D) Conditional quantile plot showing the
correlation of observed and predicted log costs of the international validation data. The shownmean deviation of log 1.3 of observed
to predicted costs corresponds to amean of 27.8%overestimation of costs. The blue columns indicate the number of patients within
the range (sections of 0.4) of predicted costs. (Natural log). (E)Correlationof observedandpredicted log cost after recalibrationof the
predictionmodel by updating the intercept by -1.3. (F) Conditional quantile plot showing the correlation of observed and predicted
log costs of the international validation data after recalibration of the prediction model by updating the intercept by -1.3.
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CCI1 for cost assessment. Finally, the study focused exclusively on
direct cost, ignoring economic implications such as time out to work
or events leading to permanent invalidity. Obviously, this must be
assessed separately.
In summary, this study suggests that cumulative cost of a
procedure strongly correlate with overall postoperative morbidity, as
quantified by the CCI1. This novel approach appears to be indepen-
dent of the health care system and cost assessment and is therefore,
internationally applicable. It may guide optimal surgical perfor-
mance in the future. Such cost assessment on the basis of cumulative
morbidity may open the door for more objective surgical quality
assessment as well as outcome improvement across the world.
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DISCUSSANTS
Han-Kwang Yang (Seoul, Korea):
I would like to start by thanking the authors for this
interesting paper.
I have the following questions:
First, it is well known that surgical procedures, which are
followed by postoperative complications, are more cost-intensive
than cases without any complications. What is the benefit of using
CCI1 for cost-correlation, instead of overall complication rate,
major complication rate or even specific potentially cost-intensive
complications? With respects to the trademark that is put on the
CCI1, you should justify why you chose to use this parameter over
another one for your analysis.
Second, the authors conclude that this model might ‘‘guide
optimal surgical performance,’’ but in respect of the previous con-
cern, there might be a problem. If the CCI1 is used as a marker to
compare costs within two or more hospitals, then this would be a high
incentive to only accept low-risk patients. So, a cost model that also
considers the fact that some surgical cases can only be carried out
with a certain higher medical and economic risk (independent from
the quality of medical care) is needed.
I would like to thank the authors for this very interesting
manuscript and the ESA for the privilege of being the first discussant
of this paper.
Response From Roxane D. Staiger (Zurich,
Switzerland):
Thank you, Prof. Yang, for these interesting questions. So far,
what we knew before conducting this study was the fact that there is a
correlation between cost and the most severe complications that
occur in a postoperative course. If we want to go further and actually
predict cost, we need to include every single complication that has
occurred because each of them has an impact on the overall cost. As
far as we know, the CCI1 is the only index that can include every
complication that has occurred. Now, if we were to only focus on the
most severe complications, the ones with a Clavien-Dindo score of 3a
and above, then we would disregard the cost of lower complications
as well as those of additional severe complications. Therefore, the
predicted cost would be underestimated.
Regarding your second question, you mentioned the fear of
risk adverse behavior, when we start to compare outcome using either
the CCI1 or cost. Of course, whenever we have a grading system,
this creates a certain amount of discomfort for us surgeons because it
mirrors our imperfections. When we start comparing outcomes, we
always need to consider the complexity of the patients involved and,
of course, make any necessary adjustments.
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Antonio D. Pinna (Bologna, Italy):
Thank you for this very nice presentation and interesting data.
Was the purpose of your study to predict cost immediately following
a complication? I foresee a fantastic opportunity to use this approach
to recalculate the cost of other procedures on a benchmark basis. For
example, it could be used to recalculate the average actual cost of a
liver transplant or liver resection. Congratulations again on your
thought-provoking study.
Response From Roxane D. Staiger (Zurich,
Switzerland):
Thank you, Prof. Pinna, for your kind comment. We did not
focus on predicting or assessing the cost immediately following the
complication. For us, the interesting timeframe is the first three
months after surgery because that is when most complications occur.
Therefore, rather than predicting the cost immediately after a com-
plication arises, we would recommend to calculate the entire costs
three months following the surgery.
With regard to your second point, our ability to calculate cost
now opens up many new possibilities, which we can take advantage
of. You mentioned benchmarking, which is indeed an option. Also,
in certain reimbursement systems, we could monitor whether the
amount of money we received actually matches the amount the
patient cost us. So, wewill need to explore now the many options that
this tool gives us.
Giovanni Zaninotto (London, United Kingdom):
Thank you very much for your clear presentation. I have the
following three questions for you:
First, the costs were calculated and validated in high-volume
academic centers. Did you ever apply the calculation of the costs to
normal hospitals?
Second, the prediction of the costs is better for complex
operations than for simple ones, such as a cholecystectomy. What
if we were to apply this type of cost calculation to other types of
operations, such as appendectomies or hernia repairs, which are the
most common?
Third, the Cost Complexity Index has only been validated in
abdominal operations. Do you have any idea whether this could be
applicable to extra abdominal operations?
Response From Roxane D. Staiger (Zurich,
Switzerland):
Thank you, Prof. Zaninotto, for your important questions.
Your first question addresses the issue how our model may
apply to non-academic institutions. While smaller institutions have
consistently lower costs than large centers due to less infrastructure,
wewould expect our model to be valid, but this needs, however, some
additional validation.
Your second question is whether the model may apply to other
procedures, particularly simple ones, such as appendectomy. We
would like to make 2 points. First, we believe that the principle may
apply to most procedures, but each would need, again, validation.
Next, perhaps we did not emphasize enough the difference between
prediction and correlation. The model is in fact as accurate for small
as it is for complex procedures. The correlation, however, was
stronger for more demanding procedures, but these correlations were
just basic statistics before we performed the prediction modelling.
Your third point about extra-abdominal procedures needs
further studies, but we would anticipate that the principle would
remain valid.
Final comment From Pierre-Alain Clavien (Zurich,
Switzerland):
I would just like to make one last comment and congratulate
Roxane for her great presentation. Today, we are overwhelmed by
administrative duties as well as figures on cost, reimbursements or
DRGs. These figures, which are difficult for us to grasp, are typically
used to request a tighter budget. The incentive behind the current study
was to develop a simple tool, which can predict costs and estimate the
real costs of specific cases. The proposed simple formula, based on
post-operative complications (CCI1) and the age of the patients, may
be seen as a new language to challenge our administration or external
payers, who continuously argue against paying for complications.
While no onewould support a system rewarding poor care, the real cost
of our work must be honored. Thus, in order to apply such a tool in our
practice, wemust first demonstrate that the quality of care is high or at
least adequate. There may be several ways to measure the quality of
care. For example, benchmark cut-offs in low risk patients have been
established for a number of oncological and surgical endpoints,
including complications, and may serve as references to judge the
quality of care at specific centers. If the center qualifies for quality
(values below the cut-offs), the proposed formula can be used as a valid
tool to assess costs for any group of patients and prevent risk avoidance
policies tomaximize good results. In order to remain plausible partners
in healthcare delivery, we must enter theworld of the health economy.
Thank you for authorizing us to present our study to this very
prestigious group of surgeons.
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